News

New CDC recommendations on hepatitis B vaccination raise concerns over increased infections and healthcare costs, complicating public health efforts.

Catch up on news headlines highlighted in the dermatology space by HCPLive in 2025 with this Year in Review.

Significant advancements in allergy treatments emerge in 2025, including 4 FDA approved treatments for hereditary angioedema.

The hepatology year in review highlights FDA approvals, MASH therapies, viral hepatitis advances, cholestatic disease shifts, and evolving clinical guidance.

Catch up on the most impactful headlines in cardiology from all of 2025 with our Year in Review.

Clinicians across specialties explain how health misinformation is reshaping patient decisions, delaying care, and undermining trust.

Potent synthetic opioids are being disguised in everyday products—from THC vapes to counterfeit pills—putting teens at unseen, lethal risk.

The FDA has approved small-molecule pyruvate kinase R activator mitapivat for the treatment of anemia in adults with alpha- or beta-thalassemia.

In 2025, FDA approvals, pivotal trials, and emerging therapies shifted nephrology care toward precision and mechanism-driven kidney medicine.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

Garvey reflects on the recent FDA approval of oral semaglutide (Wegovy) as the first GLP-1 pill for weight loss.

The approval indicates narsoplimab as the first and only treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy.

Catch up on some of the biggest alopecia areata news headlines covered by HCPLive from 2025 with this ‘Year in Review’ summary.

The hepatitis year in review covers FDA approvals, HBV and HDV breakthroughs, HCV label expansion, clinical guidelines, and vaccine policy changes.

The COPD year in review highlights FDA approvals, data, and advances in 2025.

Results of an exclusive Urology Times survey indicate heightened concern among older men about prostate cancer screening.

Catch up on the most impactful headlines in dyslipidemia from all of 2025 with our Year in Review.

The FDA has approved an sNDA for the FUROSCIX On-body Infusor in pediatric patients and accepted another for the FUROSCIX ReadyFlow Autoinjector.

A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.

A multinational survey suggests even slowly progressing C3G and IC-MPGN substantially affect patients, caregivers, and healthcare systems.

The MASH/MASLD year in review highlights FDA approvals, resmetirom data, semaglutide, pemvidutide, and advances in fibrosis and noninvasive endpoints in 2025.

Findings from a retrospective observational cohort study indicate podometrics may inform a less invasive treatment approach in IgA nephropathy (IgAN).

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

A study found that higher PM2.5 exposure during the first year after NICU discharge increased asthma risk in children with bronchopulmonary dysplasia by age 5.

The approval is based on the 64-week phase 3 OASIS 4 trial showing an average weight loss of ~17% if all patients stayed on treatment with semaglutide and ~14% regardless of if patients stayed on treatment.

Innovative therapies and devices are transforming food allergy management, enhancing safety and quality of life for patients and families.